Evolving Strategies for Treating Metastatic Non-Small Cell Lung Cancer: Focus on TROP2-Directed ADCs

home / evolving-paradigms-in-oncology / evolving-strategies-for-treating-metastatic-nsclc-focus-on-trop2-directed-adcs

Expert oncologists discuss the evolving treatment paradigm of TROP2-directed antibody drug conjugates in patients with metastatic non-small cell lung cancer.

Expert on lung cancer

EP. 1: Coming Soon: Evolving Strategies for Treating Metastatic Non-Small Cell Lung Cancer: Focus on TROP2-Directed ADCs

Anne S. Tsao, MD
September 29th 2023

Expert oncologist Anne Tsao, MD, shares her excitement for an upcoming precision medicine program focused on the evolving role of TROP2-directed antibody drug conjugates in metastatic non-small cell lung cancer.

Watch